Literature DB >> 16051862

Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype.

Bhavna Chohan1, Ludo Lavreys, Stephanie M J Rainwater, Julie Overbaugh.   

Abstract

A major premise underlying current human immunodeficiency virus type 1 (HIV-1) vaccine approaches is that preexisting HIV-1-specific immunity will block or reduce infection. However, the recent identification of several cases of HIV-1 reinfection suggests that the specific immune response generated for chronic HIV-1 infection may not be adequate to protect against infection by a second HIV-1 strain. It has been unclear, though, whether these individuals are representative of the global epidemic or are rare cases. Here we show that in a population of high-risk women, HIV-1 reinfection occurs almost as commonly as first infections. The study was designed to detect cases of reinfection by HIV-1 of a different subtype and thus captured cases where there was considerable diversity between the first and second strain. In each case, the second virus emerged approximately 1 year after the first infection, and in two cases, it emerged when viral levels were high, suggesting that a well-established HIV-1 infection may provide little benefit in terms of immunizing against reinfection, at least by more-divergent HIV-1 variants. Our findings indicate an urgent need for studies of larger cohorts to determine the incidence and timing of both intersubtype and intrasubtype reinfection.

Entities:  

Mesh:

Year:  2005        PMID: 16051862      PMCID: PMC1182664          DOI: 10.1128/JVI.79.16.10701-10708.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Incidence of HIV superinfection following primary infection.

Authors:  Davey M Smith; Joseph K Wong; George K Hightower; Caroline C Ignacio; Kersten K Koelsch; Eric S Daar; Douglas D Richman; Susan J Little
Journal:  JAMA       Date:  2004-09-08       Impact factor: 56.272

2.  Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation.

Authors:  E W Petersdorf; J A Hansen; P J Martin; A Woolfrey; M Malkki; T Gooley; B Storer; E Mickelson; A Smith; C Anasetti
Journal:  N Engl J Med       Date:  2001-12-20       Impact factor: 91.245

3.  Dual infection with different strains of the same HIV-1 subtype.

Authors:  S Buttò; C Argentini; A M Mazzella; M P Iannotti; P Leone; P Leone; A Nicolosi; G Rezza
Journal:  AIDS       Date:  1997-04       Impact factor: 4.177

4.  Dual infection with HIV-1 Thai subtype B and E.

Authors:  K Q Xin; X H Ma; K A Crandall; H Bukawa; Y Ishigatsubo; S Kawamoto; K Okuda
Journal:  Lancet       Date:  1995-11-18       Impact factor: 79.321

5.  Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group.

Authors:  R S Diaz; E C Sabino; A Mayer; J W Mosley; M P Busch
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

6.  Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.

Authors:  R Shankarappa; J B Margolick; S J Gange; A G Rodrigo; D Upchurch; H Farzadegan; P Gupta; C R Rinaldo; G H Learn; X He; X L Huang; J I Mullins
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission.

Authors:  Christine M Rousseau; Ruth W Nduati; Barbra A Richardson; Grace C John-Stewart; Dorothy A Mbori-Ngacha; Joan K Kreiss; Julie Overbaugh
Journal:  J Infect Dis       Date:  2004-10-07       Impact factor: 5.226

8.  Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans.

Authors:  A W Artenstein; T C VanCott; J R Mascola; J K Carr; P A Hegerich; J Gaywee; E Sanders-Buell; M L Robb; D E Dayhoff; S Thitivichianlert
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

9.  Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women.

Authors:  Ludo Lavreys; Jared M Baeten; Joan K Kreiss; Barbra A Richardson; Bhavna H Chohan; Wisal Hassan; Dana D Panteleeff; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh
Journal:  J Infect Dis       Date:  2004-01-09       Impact factor: 5.226

10.  Virus load during primary Human Immunodeficiency Virus (HIV) type 1 infection is related to the severity of acute HIV illness in Kenyan women.

Authors:  Ludo Lavreys; Jared M Baeten; Julie Overbaugh; Dana D Panteleeff; Bhavna H Chohan; Barbra A Richardson; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Joan K Kreiss
Journal:  Clin Infect Dis       Date:  2002-06-03       Impact factor: 9.079

View more
  48 in total

1.  Recombination between variants from genital tract and plasma: evolution of multidrug-resistant HIV type 1.

Authors:  Kimdar S Kemal; Christina M Ramirez; Harold Burger; Brian Foley; Douglas Mayers; Thomas Klimkait; François Hamy; Kathryn Anastos; Katarina Petrovic; Vladimir N Minin; Marc A Suchard; Barbara Weiser
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-10       Impact factor: 2.205

Review 2.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

3.  Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus.

Authors:  Rebecca L R Powell; Thompson Kinge; Phillipe N Nyambi
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

4.  Patterns of Human Immunodeficiency Virus type 1 recombination ex vivo provide evidence for coadaptation of distant sites, resulting in purifying selection for intersubtype recombinants during replication.

Authors:  Andrea Galli; Mary Kearney; Olga A Nikolaitchik; Sloane Yu; Mario P S Chin; Frank Maldarelli; John M Coffin; Vinay K Pathak; Wei-Shau Hu
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

Review 5.  HIV/AIDS epidemiology, pathogenesis, prevention, and treatment.

Authors:  Viviana Simon; David D Ho; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

6.  A gp41-based heteroduplex mobility assay provides rapid and accurate assessment of intrasubtype epidemiological linkage in HIV type 1 heterosexual transmission Pairs.

Authors:  Olivier Manigart; Debrah I Boeras; Etienne Karita; Paulina A Hawkins; Cheswa Vwalika; Nathan Makombe; Joseph Mulenga; Cynthia A Derdeyn; Susan Allen; Eric Hunter
Journal:  AIDS Res Hum Retroviruses       Date:  2012-07-03       Impact factor: 2.205

7.  Competition-colonization dynamics in an RNA virus.

Authors:  Samuel Ojosnegros; Niko Beerenwinkel; Tibor Antal; Martin A Nowak; Cristina Escarmís; Esteban Domingo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-13       Impact factor: 11.205

8.  Identification of HIV superinfection in seroconcordant couples in Rakai, Uganda, by use of next-generation deep sequencing.

Authors:  Andrew D Redd; Aleisha Collinson-Streng; Craig Martens; Stacy Ricklefs; Caroline E Mullis; Jordyn Manucci; Aaron A R Tobian; Ethan J Selig; Oliver Laeyendecker; Nelson Sewankambo; Ronald H Gray; David Serwadda; Maria J Wawer; Stephen F Porcella; Thomas C Quinn
Journal:  J Clin Microbiol       Date:  2011-06-22       Impact factor: 5.948

9.  Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys.

Authors:  Emmi Andersson; Wei Shao; Irene Bontell; Fatim Cham; Do Duy Cuong; Amogne Wondwossen; Lynn Morris; Gillian Hunt; Anders Sönnerborg; Silvia Bertagnolio; Frank Maldarelli; Michael R Jordan
Journal:  Infect Genet Evol       Date:  2013-04-11       Impact factor: 3.342

10.  Molecular epidemiology of HIV type 1 subtypes in Rwanda.

Authors:  Kimdar S Kemal; Kathryn Anastos; Barbara Weiser; Christina M Ramirez; Qiuhu Shi; Harold Burger
Journal:  AIDS Res Hum Retroviruses       Date:  2013-04-01       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.